Parkinson disease gene therapy moves toward the clinic

被引:35
作者
Björklund, A [1 ]
Lindvall, O [1 ]
机构
[1] Univ Lund, Wallenberg Neurosci Ctr, S-22362 Lund, Sweden
关键词
D O I
10.1038/81291
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Current therapies for Parkinson disease focus mainly on symptomatic relief, but gene therapy approaches may offer the prospect of halting or reversing the progress of the disease process itself. A recent study provides evidence that sustained delivery of glial cell line-derived neurotrophic factor to the nigrostriatal system provides neuroprotection and functional recovery in a primate model of Parkinson disease.
引用
收藏
页码:1207 / 1208
页数:2
相关论文
共 13 条
[11]   Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET [J].
Morrish, PK ;
Rakshi, JS ;
Bailey, DL ;
Sawle, GV ;
Brooks, DJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :314-319
[12]   In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin [J].
Rosenblad, C ;
Gronborg, M ;
Hansen, C ;
Blom, N ;
Meyer, M ;
Johansen, J ;
Dago, L ;
Kirik, D ;
Patel, UA ;
Lundberg, C ;
Trono, D ;
Björklund, A ;
Johansen, TE .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2000, 15 (02) :199-214
[13]   Lentiviral vectors: turning a deadly foe into a therapeutic agent [J].
Trono, D .
GENE THERAPY, 2000, 7 (01) :20-23